Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (11-20 of 318) with videos related to

Pageof 32
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 24, 2014
Radiopharmaceutical therapy in the era of precision medicineGeorge Sgouros, David M Goldenberg
Molecular Cancer Therapeutics|January 7, 2005
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapyRhona Stein, David M Goldenberg
Therapeutics and Clinical Risk Management|May 14, 2008
Targeting CD22 as a strategy for treating systemic autoimmune diseasesThomas Dörner, David M Goldenberg
Plastic and Reconstructive Surgery|March 7, 2003
Nape of neck eyebrow reconstructionBoris E Goldman, David M Goldenberg
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2005
Radioimmunotherapy of non-Hodgkin's lymphoma revisitedDavid M Goldenberg, Robert M Sharkey
Expert Opinion on Biological Therapy|June 2, 2012
Using antibodies to target cancer therapeuticsDavid M Goldenberg, Robert M Sharkey
Expert Opinion on Emerging Drugs|September 11, 2010
New agents and approaches to the treatment of B-cell non-Hodgkin lymphomaJack D Burton, David M Goldenberg
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Perspectives on cancer therapy with radiolabeled monoclonal antibodiesRobert M Sharkey, David M Goldenberg
Expert Opinion on Biological Therapy|June 12, 2012
Designing immunoconjugates for cancer therapySerengulam V Govindan, David M Goldenberg
Oncoscience|November 17, 2017
Enhancing the antitumor potency of T cells redirected by bispecific antibodiesChien-Hsing Chang, David M Goldenberg
Pageof 32

Showing results (11-20 of 318) with videos related to

Sort By:
Pageof 32
European Journal of Cancer (Oxford, England : 1990)|June 24, 2014
Radiopharmaceutical therapy in the era of precision medicineGeorge Sgouros, David M Goldenberg
Molecular Cancer Therapeutics|January 7, 2005
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapyRhona Stein, David M Goldenberg
Therapeutics and Clinical Risk Management|May 14, 2008
Targeting CD22 as a strategy for treating systemic autoimmune diseasesThomas Dörner, David M Goldenberg
Plastic and Reconstructive Surgery|March 7, 2003
Nape of neck eyebrow reconstructionBoris E Goldman, David M Goldenberg
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2005
Radioimmunotherapy of non-Hodgkin's lymphoma revisitedDavid M Goldenberg, Robert M Sharkey
Expert Opinion on Biological Therapy|June 2, 2012
Using antibodies to target cancer therapeuticsDavid M Goldenberg, Robert M Sharkey
Expert Opinion on Emerging Drugs|September 11, 2010
New agents and approaches to the treatment of B-cell non-Hodgkin lymphomaJack D Burton, David M Goldenberg
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Perspectives on cancer therapy with radiolabeled monoclonal antibodiesRobert M Sharkey, David M Goldenberg
Expert Opinion on Biological Therapy|June 12, 2012
Designing immunoconjugates for cancer therapySerengulam V Govindan, David M Goldenberg
Oncoscience|November 17, 2017
Enhancing the antitumor potency of T cells redirected by bispecific antibodiesChien-Hsing Chang, David M Goldenberg
Pageof 32